Recent developments in pediatric neuro-oncology.
Although brain tumors represent the second most common malignancy in childhood, there are only 1200 to 1500 children diagnosed with brain tumors each year in the US. Approximately 50% of these children are treated at university or cancer treatment centers. Thus, therapeutic trials by default rather than design have been restricted to small numbers of patients. Information on histopathologic groupings, incidence of various tumor types according to age, general treatment trends and survival statistics are available from the Surveillance, Epidemiology, and End Results (SEER) registries of the National Cancer Institute. Although survivals in brain tumor cancers are worse than in other forms of childhood cancer, treatment advances in surgery, radiation and chemotherapy have significantly improved survivals in at least one brain tumor of childhood, medulloblastoma. Ironically, this treatment may have significant long-term adverse effects on intellect, endocrine function, and on the development of second malignancies. Prompt recognition of these delayed effects is of clinical importance, as some effects are amenable to treatment and others may be prevented by careful monitoring of drug and radiation administration.
D000293:Adolescent; D000367:Age Factors; D001254:Astrocytoma / Q000628:therapy; D001921:Brain / Q000528:radiation effects; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002528:Cerebellar Neoplasms / Q000401:mortality / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D004700:Endocrine System Diseases / Q000209:etiology; D013006:Growth Hormone / Q000172:deficiency; D006801:Humans; D007223:Infant; D007859:Learning Disabilities / Q000209:etiology; D008527:Medulloblastoma / Q000401:mortality / Q000628:therapy; D009381:Neoplasms, Radiation-Induced / Q000453:epidemiology; D012042:Registries; D012306:Risk
D013006:Growth Hormone